PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

The PI3K–AKT–mTOR pathway is frequently activated in cancer. PI3K inhibitors, including the pan-PI3K inhibitor buparlisib (BKM120) and the PI3Kα-selective inhibitor alpelisib (BYL719), currently in clinical development by Novartis Oncology, may therefore be effective as anticancer agents. Early clin...

Descripción completa

Detalles Bibliográficos
Autores principales: Massacesi, Cristian, Di Tomaso, Emmanuelle, Urban, Patrick, Germa, Caroline, Quadt, Cornelia, Trandafir, Lucia, Aimone, Paola, Fretault, Nathalie, Dharan, Bharani, Tavorath, Ranjana, Hirawat, Samit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708174/
https://www.ncbi.nlm.nih.gov/pubmed/26793003
http://dx.doi.org/10.2147/OTT.S89967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708174/
https://www.ncbi.nlm.nih.gov/pubmed/26793003
http://dx.doi.org/10.2147/OTT.S89967

Ejemplares similares